Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Non-GCB/ABC Diffuse Large B-Cell Lymphoma Clinical Trial

Official title: Zanubrutinib Combination With R-CHOP in Treating Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Status Recruiting

Clinical Trial Summary

Aim of this study will evaluate the efficacy and safety of zanubrutinib in combination with R-CHOP for newly diagnosed untreated Non-GCB DLBCL Patients

Clinical Trial Description

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. According to Hans' algorithms, DLBCL can be identified as 2 subtypes: germinal b-cell-like(GCB) and non-germinal b-cell-like(non-GCB). Approximately 50 to 60% of DLBCL was non-GCB subtype DLBCL.The non-GCB DLBCL revealed poor clinical outcomes. Bruton's tyrosine kinase (BTK) inhibitors have established therapeutic activity in B cell malignancies, with potential activity in non-GCB DLBCL. This study will evaluate the efficacy and safety of zanubrutinib in combination with R-CHOP for newly diagnosed untreated Non-GCB DLBCL Patients. ;

Related Conditions & MeSH terms

• Lymphoma, Large B-Cell, Diffuse
• Non-GCB/ABC Diffuse Large B-Cell Lymphoma

• NCT number: NCT04835870
• Study type: Interventional
• Source: The First Affiliated Hospital of Soochow University
• Contact: Caixia Li, M.D
• Phone: +86 512 67781856
• Email: licaixia@suda.edu.cn
• Status: Recruiting
• Phase: Phase 2
• Start date: April 1, 2021
• Completion date: October 1, 2025